DK1497330T3 - Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein - Google Patents

Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein

Info

Publication number
DK1497330T3
DK1497330T3 DK03725109.7T DK03725109T DK1497330T3 DK 1497330 T3 DK1497330 T3 DK 1497330T3 DK 03725109 T DK03725109 T DK 03725109T DK 1497330 T3 DK1497330 T3 DK 1497330T3
Authority
DK
Denmark
Prior art keywords
factor viii
interaction
antagonists
low
lrp
Prior art date
Application number
DK03725109.7T
Other languages
Danish (da)
English (en)
Inventor
Koenraad Mertens
Arend Niels Bovenschen
Jan Voorberg
Manfred Rieger
Friedrich Scheiflinger
Original Assignee
Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin Bloedvoorziening filed Critical Sanquin Bloedvoorziening
Application granted granted Critical
Publication of DK1497330T3 publication Critical patent/DK1497330T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03725109.7T 2002-04-29 2003-04-28 Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein DK1497330T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37635102P 2002-04-29 2002-04-29
PCT/EP2003/004425 WO2003093313A2 (en) 2002-04-29 2003-04-28 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein

Publications (1)

Publication Number Publication Date
DK1497330T3 true DK1497330T3 (da) 2010-06-14

Family

ID=29401334

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03725109.7T DK1497330T3 (da) 2002-04-29 2003-04-28 Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein

Country Status (10)

Country Link
US (1) US8586538B2 (enExample)
EP (1) EP1497330B1 (enExample)
JP (2) JP2005535588A (enExample)
AT (1) ATE463514T1 (enExample)
AU (1) AU2003227687B2 (enExample)
CA (1) CA2484155C (enExample)
DE (1) DE60332011D1 (enExample)
DK (1) DK1497330T3 (enExample)
ES (1) ES2343681T3 (enExample)
WO (1) WO2003093313A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1454632A1 (en) * 2003-02-07 2004-09-08 Aventis Behring GmbH, Intellectual Property/Legal Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006003183A1 (de) * 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009274958A (ja) 2006-08-31 2009-11-26 Nara Prefecture 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
JP5674650B2 (ja) * 2008-06-04 2015-02-25 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
JP5394864B2 (ja) * 2009-09-10 2014-01-22 アスモ株式会社 モータ
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507664A (ja) * 1995-06-12 1999-07-06 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 第ｖｉｉｉ因子由来の第ｉｘ因子結合ペプチド及び血液凝固のインヒビターとしてのそれらの使用
AU760678B2 (en) * 1998-05-08 2003-05-22 Stichting Sanquin Bloedvoorziening Method for diagnosis and treatment of haemophilia a patients with an inhibitor
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DK1129186T4 (da) * 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet

Also Published As

Publication number Publication date
CA2484155A1 (en) 2003-11-13
JP2010202664A (ja) 2010-09-16
US20080219983A1 (en) 2008-09-11
CA2484155C (en) 2015-10-13
ATE463514T1 (de) 2010-04-15
EP1497330B1 (en) 2010-04-07
WO2003093313A3 (en) 2004-07-29
WO2003093313A2 (en) 2003-11-13
EP1497330A2 (en) 2005-01-19
AU2003227687A1 (en) 2003-11-17
AU2003227687B2 (en) 2009-10-15
ES2343681T3 (es) 2010-08-06
JP2005535588A (ja) 2005-11-24
DE60332011D1 (de) 2010-05-20
US8586538B2 (en) 2013-11-19

Similar Documents

Publication Publication Date Title
WO2003093313A3 (en) Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
CY1111725T1 (el) ΧΙΜΑΙΡΙΚΕΣ ΠΡΩΤΕÏΝΕΣ ΠΑΡΑΓΟΝΤΑ ΠΗΞΗΣ VII-Fc ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΜΙΑΣ ΑΙΜΟΣΤΑΤΙΚΗΣ ΔΙΑΤΑΡΑΧΗΣ
EA201100072A1 (ru) Новые композиции и способы
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
CY1106879T1 (el) Χρηση των αναστολεων αναγωγασης συνενζυμου α 3-υδροξυ-3-μεθυλογλουταρυλ για την παρασκευη ενος φαρμακου για την αντιμετωπιση της διαβητικης νευροπαθειας
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
EA200500782A1 (ru) Лечение геморрагического шока
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
UY27780A1 (es) Uso de anticuerpos anti-tnf alfa y otro fármaco
EA200971053A1 (ru) Способы лечения кожных язв
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
WO2004075838A3 (en) Method and compositions for the treatment of meconium aspiration syndrome
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden